For patients with metastatic NSCLC with MET amplification who respond well to first line crizotinib but develop hepatotoxicity, how do you decided whether to consider re-challenge or change therapy altogether?

Topics: Lung Cancer • Medical Oncology

Answer from: Medical Oncologist at Community Practice

I think it depends on degree of hepatotoxicity, if lower grade isolated ALT/AST that recovers, would dose reduce and resume and monitor labs weekly initially. For high grade or elevated Tbili with slow recovery, may have to start at very low dose (200-250mg daily and uptitrate as LFT allow). This is...

Related Questions